0001145549-21-015576.txt : 20210311 0001145549-21-015576.hdr.sgml : 20210311 20210311124916 ACCESSION NUMBER: 0001145549-21-015576 CONFORMED SUBMISSION TYPE: N-CEN PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20201231 FILED AS OF DATE: 20210311 DATE AS OF CHANGE: 20210311 EFFECTIVENESS DATE: 20210311 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GDL FUND CENTRAL INDEX KEY: 0001378701 IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: N-CEN SEC ACT: 1940 Act SEC FILE NUMBER: 811-21969 FILM NUMBER: 21732591 BUSINESS ADDRESS: STREET 1: ONE CORPORATE CENTER CITY: RYE STATE: NY ZIP: 10580 BUSINESS PHONE: 914-921-5100 MAIL ADDRESS: STREET 1: ONE CORPORATE CENTER CITY: RYE STATE: NY ZIP: 10580 FORMER COMPANY: FORMER CONFORMED NAME: Gabelli Global Deal Fund DATE OF NAME CHANGE: 20061019 N-CEN 1 primary_doc.xml X0303 N-CEN LIVE 0001378701 XXXXXXXX false false false N-2 GDL Fund 811-21969 0001378701 5493000XKGL8ZPN99479 One Corporate Center Rye 10580-1422 US-NY US 1-800-422-3554 The Bank of New York Mellon 240 Greenwich Street New York 10286 1-212-495-1784 Custody BNY Mellon Investment Servicing (US) Inc. 301 Bellevue Parkway Wilmington 19809 1-302-791-1700 Accounting Gabelli Funds, LLC One Corporate Center Rye 10580-1422 914-921-5100 Accounting American Stock Transfer & Trust Company, LLC 6201 15th Avenue Brooklyn 11219 800-937-5449 Transfer Agent N N N-2 Y Anthony S. Colavita N/A Y James P. Conn N/A N Leslie F. Foley N/A N Michael J. Melarkey N/A N Salvatore J. Zizza N/A N Mario J. Gabelli 000216136 Y Clarence A. Davis N/A N Edward T. Tokar N/A Y Richard J. Walz 001392836 One Corporate Center Rye 10580 XXXXXX N N N N N N N Ernst & Young LLP 42 N/A N N N N N GDL Fund 5493000XKGL8ZPN99479 N 0 0 0 N/A N N Y N N/A N/A N/A Rule 17e-1 (17 CFR 270.17e-1) N N N N Gabelli Funds, LLC 801-37706 000104949 549300JDTNRQK8NMTG03 N American Stock Transfer & Trust Company, LLC 084-00416 254900TS5EWP83BEOU02 N N N Intercontinental Exchange, Inc. 5493000F4ZO33MV32P92 N N The Bank of New York Mellon HPFHU0OQ28E4N0NFVK49 N N Bank - section 17(f)(1) (15 U.S.C. 80a-17(f)(1)) N American Stock Transfer & Trust Company, LLC 254900TS5EWP83BEOU02 N N N BNY Mellon Investment Servicing (US) Inc. 549300CFZQLI9QMJ1Z03 N Y Gabelli Funds, LLC 549300JDTNRQK8NMTG03 Y N N G.Research, LLC 008-21373 000007353 N/A 42190.000000000000 G.distributors, LLC 008-68697 000155071 N/A 0.000000000000 STONEX FINANCIAL INC. 008-51269 000045993 549300LNKU6K5TJCRG93 13963.000000000000 WELLS FARGO CLEARING SERVICES, LLC 008-37180 000019616 88KRVSOEKUGQZJ3DKW55 14910.000000000000 G.RESEARCH, LLC 008-21373 000007353 N/A 42190.000000000000 Cowen and Company, LLC 008-22522 000007616 549300WR155U7DVMIW58 16163.000000000000 MORGAN STANLEY & CO. LLC 008-15869 000008209 9R7GPTSO7KV3UQJZQ078 25147.000000000000 Raymond James & Associates, Inc. 008-10999 000000705 U4ONQX15J3RO8XCKE979 12413.000000000000 UBS Securities LLC 008-22651 000007654 T6FIZBDPKLYJKFCRVK44 10675.000000000000 GOLDMAN SACHS & CO. LLC 008-00129 000000361 FOR8UP27PHTHYVLBNG30 11952.000000000000 J.P. Morgan Securities LLC 008-35008 000000079 ZBUT11V806EZRVTWT807 11089.000000000000 BARCLAYS CAPITAL, INC. 008-41342 000019714 AC28XWWI3WIBK2824319 11440.000000000000 218974.000000000000 ZF Friedrichshafen AG N/A N/A 529900CAYOWB8YIG7X25 DE 9418500.000000000000 ADVENT INTERNATIONAL CORPORATION N/A N/A 549300IXPCRIG6GX2F40 9627232.000000000000 Novartis AG N/A N/A 5493007HIVTX6SY6XD66 CH 15300000.000000000000 Astellas Pharma Inc. N/A N/A 529900IB708DY2HBBB35 JP 15222000.000000000000 TALLGRASS ENERGY PARTNERS, LP N/A N/A 549300IQ3DN0F3VERF65 29409500.000000000000 Daiwa Capital Markets America, Inc. 008-12242 000001576 M67H5PRC0NQKM73ZAS82 162032748.000000000000 RBC CAPITAL MARKETS LLC 008-45411 000031194 549300LCO2FLSSVFFR64 106427917.000000000000 NOMURA SECURITIES INTERNATIONAL, INC. 008-15255 000004297 OXTKY6Q8X53C9ILVV871 218213227.000000000000 BMO CAPITAL MARKETS CORP. 008-34344 000016686 RUC0QBLBRPRCU4W1NE59 31811931.000000000000 BARCLAYS CAPITAL, INC. 008-41342 000019714 AC28XWWI3WIBK2824319 322100903.000000000000 1142048329.000000000000 Y 214484671.000000000000 0.000000000000 Common stock C000000000 Preferred stock 4.00% Series C Cumulative Puttable & Callable Preferred Shares N N Common stock N N N 0.790000000000 3.170000000000 8.72 10.740000000000 true INTERNAL CONTROL RPT 2 internalcontrolrpt_gdl.htm

  

  

Report of Independent Registered Public Accounting Firm 

  

To the Shareholders and  

Board of Trustees of The GDL Fund  

  

In planning and performing our audit of the financial statements of The GDL Fund (the “Fund”) as of and for the year ended December 31, 2020, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), we considered the Fund’s internal control over financial reporting, including controls over safeguarding securities, as a basis for designing our auditing procedures for the purpose of expressing our opinion on the financial statements and to comply with the requirements of Form N-CEN, but not for the purpose of expressing an opinion on the effectiveness of the Fund’s internal control over financial reporting. Accordingly, we express no such opinion.   

  

The management of the Fund is responsible for establishing and maintaining effective internal control over financial reporting. In fulfilling this responsibility, estimates and judgments by management are required to assess the expected benefits and related costs of controls. A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and trustees of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of a company’s assets that could have a material effect on the financial statements. 

  

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. 

  

A deficiency in internal control over financial reporting exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent or detect misstatements on a timely basis. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Fund’s annual or interim financial statements will not be prevented or detected on a timely basis.  

  

Our consideration of the Fund’s internal control over financial reporting was for the limited purpose described in the first paragraph and would not necessarily disclose all deficiencies in internal control that might be material weaknesses under standards established by the PCAOB. However, we noted no deficiencies in the Fund’s internal control over financial reporting and its operation, including controls over safeguarding securities, that we consider to be a material weakness as defined above as of December 31, 2020. 

  

This report is intended solely for the information and use of management and the Board of Trustees of The GDL Fund and the Securities and Exchange Commission and is not intended to be and should not be used by anyone other than these specified parties. 

  

  

  

  

  

/s/ Ernst & Young LLP 

Philadelphia, Pennsylvania 

February 26, 2021